Rezolute (Nasdaq:RZLT) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

RZLT 주식 개요

는 미국에서 만성 포도당 불균형과 관련된 대사 질환 치료제를 개발하는 임상 단계의 바이오 제약 회사입니다.

RZLT 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	2/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 92.7% 에서 거래

수익은 연간 76.83% 증가할 것으로 예상됩니다.

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

지난 1년 동안 주주가 크게 희석되었습니다.

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

최근 3개월간 주가 변동성

Rezolute, Inc. 경쟁사

Abeona Therapeutics

NasdaqCM:ABEO

US$243.4m

Sera Prognostics

NasdaqGM:SERA

US$243.6m

ESSA Pharma

NasdaqCM:EPIX

US$257.8m

Enanta Pharmaceuticals

NasdaqGS:ENTA

US$246.4m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Rezolute
과거 주가
현재 주가	US$5.20
52주 최고치	US$6.10
52주 최저치	US$0.72
베타	1.19
11개월 변경	19.54%
3개월 변경 사항	-5.11%
1년 변경 사항	263.64%
33년 변화	-47.42%
5년 변화	-25.71%
IPO 이후 변화	-99.21%

최근 뉴스 및 업데이트

Recent updates

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

May 22

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Feb 13

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Sep 21

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

Jan 12

주주 수익률

	RZLT	US Biotechs	US 마켓
7D	10.6%	-1.9%	-3.4%
1Y	263.6%	13.9%	19.6%

수익률 대 산업: RZLT 지난 1년 동안 6.7 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: RZLT 지난 1년 동안 23.3 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is RZLT's price volatile compared to industry and market?
RZLT volatility
RZLT Average Weekly Movement	11.8%
Biotechs Industry Average Movement	10.4%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	3.1%

안정적인 주가: RZLT 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: RZLT 의 주간 변동성( 10% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2010	41	Nevan Elam	www.rezolutebio.com

임상 단계의 바이오 제약 회사인 리졸루트는 미국에서 만성 포도당 불균형과 관련된 대사 질환 치료제를 개발하는 회사입니다. 이 회사의 주요 제품 후보는 극히 드문 소아 유전 질환인 선천성 고인슐린증 치료를 위한 임상 2b상 시험 중인 인간 단일 클론 항체 RZ358입니다. 또한 만성 당뇨병성 황반부종 치료를 위한 경구용 혈장 칼리크레인 억제제인 RZ402를 개발 중이며 임상시험을 진행 중입니다.

Rezolute, Inc. 기본 사항 요약

Rezolute 의 수익과 매출은 시가총액과 어떻게 비교하나요?
RZLT 기본 통계
시가총액	US$293.95m
수익(TTM)	-US$58.21m
수익(TTM)	n/a

0.0x

P/S 비율

-4.9x

P/E 비율

RZLT 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
RZLT 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$58.21m
수익	-US$58.21m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.05
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

RZLT 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

RZLT 주식 개요

보상

위험 분석

Rezolute, Inc. 경쟁사

NasdaqCM:ABEO

US$243.4m

NasdaqGM:SERA

US$243.6m

NasdaqCM:EPIX

US$257.8m

NasdaqGS:ENTA

US$246.4m

가격 내역 및 성능

최근 뉴스 및 업데이트

Price target increased by 8.1% to US$11.89

New major risk - Shareholder dilution

Rezolute, Inc. Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute, Inc. announced that it expects to receive $6 million in funding

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $59.99625 million.

New major risk - Share price stability

Recent updates

Price target increased by 8.1% to US$11.89

New major risk - Shareholder dilution

Rezolute, Inc. Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute, Inc. announced that it expects to receive $6 million in funding

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $59.99625 million.

New major risk - Share price stability

Price target increased by 9.4% to US$10.57

Rezolute, Inc. Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

Rezolute, Inc., Annual General Meeting, May 16, 2024

Director recently bought US$70k worth of stock

Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Chief Financial Officer recently bought US$67k worth of stock

Price target increased by 9.0% to US$8.50

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Now 29% overvalued after recent price rise

Rezolute, Inc. Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute, Inc. Appoints Daron Evans as Chief Financial Officer

Rezolute, Inc. Announces Completion of Enrollment in its RZ402 Phase 2 Study in Diabetic Macular Edema

Rezolute Receives a Written Notice from the Listing Qualifications Department of Nasdaq Stock Market

New minor risk - Shareholder dilution

New minor risk - Share price stability

Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation

New major risk - Revenue and earnings growth

Price target decreased by 30% to US$7.80

Rezolute, Inc. Provides an Update on Its Clinical Development Plans for RZ358

Rezolute, Inc. to Report Q3, 2023 Results on May 11, 2023

Price target decreased by 7.9% to US$11.60

We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth

Rezolute, Inc. Announces Initiation of A Phase 2 Study of Rz402 in Patients with Diabetic Macular Edema

High number of new and inexperienced directors

Price target decreased to US$12.60

Rezolute GAAP EPS of -$0.37

Rezolute, Inc. Promotes Brian Roberts to Chief Medical Officer

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Price target decreased to US$19.20

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $117.587085 million.

Rezolute, Inc. Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism

Rezolute, Inc., Annual General Meeting, Jun 30, 2022

High number of new and inexperienced directors

Rezolute, Inc Announces Positive Study Results for RZ402, an oral PKI being developed for DME

Rezolute, Inc. Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies At ESPE 2021

Rezolute, Inc. Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism

Rezolute, Inc. Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME

Price target decreased to US$26.50

High number of new and inexperienced directors

Price target decreased to US$27.00

We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate

Rezolute, Inc. Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema

Rezolute shares rise on positive topline results from RZ402 eye disease trial

Rezolute, Inc. Announces Board Appointments

New 90-day low: US$11.98

Rezolute, Inc. Announces Phase 2B Study of RZ358 Continues to Enroll Congenital Hyperinsulinism (HI) Patients Worldwide

Rezolute Announces Initiation of Phase 1 Study of RZ402 for the Treatment of Diabetic Macular Edema

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

New 90-day low: US$12.94

Rezolute, Inc. Announces Resignation of Jung-Hee Lim as a Member of the Board of Directors, Audit Committee and Compensation Committee